MCC’s new White Paper looks at developing metrics specifically for vendor oversight due to the revision to GCP-ICH E6 (R2), and the impact the revision will have on the way metrics are defined and used. The MCC Vendor Oversight Work Group, formed in early 2017 at the request of industry and consortium members, was interested in taking current metrics that focus on individual trials and developing them specifically for vendor oversight. The work group also realized that the growing integration among clinical trial systems meant there were greater opportunities to implement metrics that use data from different systems to report new metrics that give greater insights.
Click Here to download the white paper.
To learn more about this work group, visit the Vendor Oversight home page.